Figure 1. NCI-H1975




Figure 2. HCC827




Figure 3. HCC827




Figure 4. H226






Figure 5. HCC827-ER


A




B




C




1: HCC827
2: HCC827-ER

Figure 6. HCC827-ER





Figure 7. HCC827-ER




| Cell line | EGFR ABC |
|---|---|
| HCC827 parent | 655K |
| HCC827-ER | 190K |
| HCC827-ER-E4 | 53K |

Figure 8. HCC827-ER




Figure 9. HCC827-ER




Figure 10. SW620




Figure 11. Detroit562






Figure 12. HCC827, ER and EPR (Aichi)

A




B




C





Figure 13. H2228

A




| Drug | EC50 |
|---|---|
| Erlotinib | 2.61E-05 |
| Crizotinib | 3.82E-06 |

B

